Wuxi AppTec's 2025 Net Profit Surges Over 100% with Plans for High Dividend and Revenue Growth Forecast for 2026

WuXi AppTec’s recent 2025 financial report shows the company achieved an annual revenue of 45.456 billion yuan, a year-on-year increase of 15.84%. Net profit attributable to shareholders of the parent company reached 19.151 billion yuan, a significant increase of 102.65% year-on-year. This performance not only far exceeded market expectations but also further solidified the company’s leading position in the global pharmaceutical R&D outsourcing industry.

As WuXi AppTec’s core segment, the chemical business contributed over 80% of the revenue in 2025. Among them, the TIDES business (oligonucleotides and peptides) performed particularly well, with annual revenue increasing by 96.0% year-on-year, becoming the main driver of the company’s growth. Meanwhile, the small molecule CDMO business maintained steady development, with an increasing proportion of late-stage clinical and commercial projects, providing stable cash flow for the company.

The impact of non-recurring gains and losses on net profit was also significant. During the reporting period, the company realized substantial investment income through the sale of some equity in its joint venture WuXi Heli and the divestment of non-core clinical businesses. These strategic moves not only optimized the company’s business structure but also enhanced profitability.

The advantages of global deployment were fully reflected in 2025. Benefiting from improved global healthcare investment and financing environment, as well as record-high licensing transaction volume for Chinese innovative drugs going overseas, WuXi AppTec’s overseas revenue share exceeded 60%. Gross profit margin increased by 4.73 percentage points year-on-year to 51.73%, driving a 26.08% year-on-year growth in overseas revenue. These achievements are attributed to the company’s deep cultivation in markets such as North America and Europe over many years.

In terms of shareholder returns, WuXi AppTec demonstrated strong sincerity. The company plans to distribute a cash dividend of 15.7927 yuan (including tax) per 10 shares to all shareholders, totaling approximately 4.712 billion yuan, with a cash dividend payout ratio of 24.6%. When combined with interim and special dividends, the total cash dividends for 2025 will reach 6.755 billion yuan. The company also plans to repurchase and cancel 2 billion yuan worth of shares through centralized bidding, with the total amount of cash dividends and buyback cancellations accounting for 45.72% of net profit.

Ample cash flow provides a solid foundation for the company’s strategic implementation. As of the end of 2025, WuXi AppTec’s cash and cash equivalents totaled 35.131 billion yuan, a year-on-year increase of 91.74%, accounting for 34.07% of total assets. The company stated that this was mainly due to the growth of free cash flow driven by high-quality business development and active capital operations such as H-share placements. To further improve capital efficiency, the company plans to use no more than 18 billion yuan of idle proprietary funds for cash management, focusing on low-risk, short-term financial products.

The continuous growth of order backlog injects strong momentum into the company’s future development. By the end of 2025, the company’s order book was approximately 58 billion yuan, a year-on-year increase of 28.8%, setting a new record. Based on a positive outlook on the market environment, WuXi AppTec expects total revenue in 2026 to reach between 51.3 billion and 53 billion yuan, with ongoing business revenue growing by 18% to 22% year-on-year.

Looking ahead, WuXi AppTec will continue to focus on its core CRDMO strategy, accelerate global capacity building and deployment, and continuously improve operational efficiency through digital transformation and lean management. As of the latest closing, the company’s A-share stock price was 87.79 yuan per share, with a total market value of 261.9 billion yuan.